To inspire and empower millions of people living with Parkinson’s around the world, Bial launches a touching campaign for the World Parkinson’s Day showing that it is possible to live a normal life, and successfully perform everyday tasks
Imagine being unable to control your own body. In your mind, everything is exactly like it was; but your brain seems to have forgotten how to tell your body to do everyday tasks like tying up shoes or using a toothbrush.
This is how it feels to live with Parkinson’s. A real challenge for the 10 million people diagnosed with Parkinson’s around the world. Parkinson’s is a progressive neurodegenerative disease – an illness that affects nerve cells in the brain. For those who live with these symptoms and for their families, Parkinson’s means much more than just physical symptoms: it also means a loss of their independence.
In order to raise awareness and help people keep their self-esteem, people with Parkinson’s were invited to star in a video that shows them at their best by focusing on what they can do instead of what they cannot do. Buttoning up shirts, putting on make-up, tying up shoes or even dancing and playing musical instruments. Simple, everyday tasks alongside a cheerful, feel-good tune developed specially for the campaign.
António Portela, CEO of Bial, explains the positive tone of the campaign: “Parkinson’s can really change people’s lives, but it’s very important that they do not lose their self-esteem. That is why we wanted to counter the negative portraits of people with Parkinson’s and show everyone what they really can do. Hopefully, we can inspire and empower the millions of people living with Parkinson’s to never give up on their dignity. Bial’s aim is to help the lives of people with Parkinson’s even if it’s to help with one small thing at a time.”
The campaign launches worldwide today – on World Parkinson’s Day – and is featured on Bial’s website, across Bial’s social media and on the European Parkinson’s Disease Association’s social media channels too.
Watch the video ‘Me at my best’ below
This article is sponsored by Bial. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Founded in 1924, Bial’s mission is to discover, develop and provide therapeutic solutions within the area of health. In recent decades, Bial has strategically focused on quality, innovation and internationalisation. Bial has channelled more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system.
In 2016 Bial launched Opicapone for Parkinson’s disease. Already available in Germany and in the United Kingdom, it will be introduced in the remaining European countries throughout 2017.
Currently representing around two thirds of its turnover, Bial will continue to strengthen its international presence based in its own innovative medicines, particularly in the most important European pharmaceutical markets, Spain, Germany, United Kingdom and Italy, where the company is already present with its own affiliates. For more information about Bial, please visit www.bial.com.
Parkinson’s campaigners win fight to have life-changing drug approved
Drug that can “transform” lives is approved for use in Scotland
2 days ago
Musical therapy study to receive $20 million in funding
The National Institutes of Health (NIH) is donating US $20 million to a medical trial researching the effects of musical therapy on brain conditions, including Parkinson’s. The trial will be carried out by the Sound Health initiative, a joint partnership between the NIH and The John F Kennedy Center for the Performing Arts. The initiative was created to expand current knowledge of how listening, performing and creating music could be harnessed for health and wellness. Francis S. Collins, director of the NIH, said: “We know that the beat of a metronome can steady the gait of someone with Parkinson’s disease, for example, but we don’t fully understand how that happens. “If we can pinpoint in the brain how music therapy works through the use of imaging and biomarkers, the hope is that we can improve its effectiveness and apply it more broadly to improve the lives of millions of people.”
Researchers develop automated system to diagnose Parkinson’s
In an international study, researchers from the US, Germany and Austria have used a non-invasive MRI method to develop an automated system that can diagnose Parkinson’s. As part of the study – published in medical journal ‘The Lancet Digital Health’ – researchers worked with 1,002 patients and used an imaging method that measures how water molecules diffuse in the brain. This helped them to identify where neurodegeneration is occurring. Researchers hope this will help improve the accuracy of early Parkinson’s diagnoses – which they estimate to be around 58%. Dr David Vaillancourt, who led the study, said: “Our method may help to reduce the number of misdiagnosed cases in the future. Since these diseases require unique treatment plans and different medications, and clinical trials testing new medications require the correct diagnosis, getting it right is important for patient care.”
MJFF announces $10 million competition for Parkinson’s
The Michael J Fox Foundation has launched the ‘Ken Griffin Alpha-synuclein Imaging Competition’ – a US $10 million programme aiming to develop a game-changing tool for Parkinson’s research. As part of the competition, participating teams will compete in a scientific race to build a device that is able to identify alpha-synuclein – a protein closely associated with Parkinson’s. Although almost everyone diagnosed with Parkinson’s has clumps of alpha-synuclein in the brain, these are currently only visible when analysing tissue during autopsies. The competition is named after Ken Griffin, CEO of US investment firm Citadel who has given US $7.5 million funding to the programme. Griffin – whose father has Parkinson’s – said: “If we have the imaging capability to observe the pathology that arises from protein-misfolding in real time, and understand how drugs are impacting people in real time, that would be a major advance.”